title: Impact of IL28B polymorphisms on response to peginterferon and ribavirin in HIV–hepatitis C virus-coinfected patients with prior nonresponse or relapse.
abstract: IL28B polymorphisms predict treatment response in chronic hepatitis C. However, no information exists in prior treatment failures. A total of 62 HIV/hepatitis C virus (HCV) patients who completed retreatment with peginterferon-α/ribavirin were examined, of whom 25 (40%) had been cured. Predictors of response [odds ratio, OR (95% confidence interval, CI)] were HCV genotypes 2/3 [16.1 (2.7-90.9)], prior relapse [9.6 (1.5-62.4)] and ribavirin plasma trough concentrations at week 4 [4.9 (1.3-18.4)]. IL28B-CC only predicted response in prior nonresponders carrying HCV genotypes 1/4 [25.1 (1.9-337)].
authors.affiliation: Hospital Carlos III, Madrid, Spain.
authors.forename: Pablo
authors.initials: P
authors.lastname: Labarga
authors.forename: Pablo
authors.initials: P
authors.lastname: Barreiro
authors.forename: José A
authors.initials: JA
authors.lastname: Mira
authors.forename: Eugenia
authors.initials: E
authors.lastname: Vispo
authors.forename: Norma
authors.initials: N
authors.lastname: Rallón
authors.forename: Karin
authors.initials: K
authors.lastname: Neukam
authors.forename: Angela
authors.initials: A
authors.lastname: Camacho
authors.forename: Antonio
authors.initials: A
authors.lastname: Caruz
authors.forename: Sonia
authors.initials: S
authors.lastname: Rodriguez-Novoa
authors.forename: Javier
authors.initials: J
authors.lastname: Pinilla
authors.forename: Antonio
authors.initials: A
authors.lastname: Rivero
authors.forename: José M
authors.initials: JM
authors.lastname: Benito
authors.forename: Juan A
authors.initials: JA
authors.lastname: Pineda
authors.forename: Vincent
authors.initials: V
authors.lastname: Soriano
mesh_terms: D017088:AIDS-Related Opportunistic Infections / Q000188:drug therapy* / Q000235:genetics; D000328:Adult; D000998:Antiviral Agents / Q000008:administration & dosage*; D004359:Drug Therapy, Combination; D005260:Female; D015658:HIV Infections / Q000188:drug therapy* / Q000235:genetics; D019698:Hepatitis C, Chronic / Q000188:drug therapy* / Q000235:genetics; D006801:Humans; D000077190:Interferon alpha-2; D016898:Interferon-alpha / Q000008:administration & dosage*; D008297:Male; D011092:Polyethylene Glycols / Q000008:administration & dosage*; D011110:Polymorphism, Genetic / Q000235:genetics; D011994:Recombinant Proteins; D012008:Recurrence; D012254:Ribavirin / Q000008:administration & dosage*
chemical_list: D000998:Antiviral Agents; D000077190:Interferon alpha-2; D016898:Interferon-alpha; D011994:Recombinant Proteins; D011092:Polyethylene Glycols; D012254:Ribavirin; C100416:peginterferon alfa-2a